Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.7-year median follow-up period. Ann Arbor stage IV and high age-adjusted international prognostic index were predictive of adverse outcome in univariate analysis. In multivariate analysis using a Cox model, only aa-IPI predicted long-term survival. While based on a limited number of cases, we suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL. We also suggested that positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some in PB-DLBCL patients. Our study based on a homogeneous cohort of PB-DLBCL patients confirmed the favorable outcome of this DLBCL variant and support the implementation of prospective clinical trials in this disease.
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Sylvain
S
Pilorge
c Lymphoid Malignancies Unit , Saint Louis Hospital , Paris , France.
Stephanie
S
Harel
d Gustave Roussy Institute , Villejuif , Paris, France.
Vincent
V
Ribrag
b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.|e Pathology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.
Frédérique
F
Larousserie
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Lise
L
Willems
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Patricia
P
Franchi
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Marielle
M
Legoff
b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.|f Orthopedic Surgery Department , Cochin Hospital, AP-HP , Paris, France.
David
D
Biau
b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.|f Orthopedic Surgery Department , Cochin Hospital, AP-HP , Paris, France.
Philippe
P
Anract
b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.|g Rhumatology Department , Cochin Hospital, AP-HP , Paris, France.
Christian
C
Roux
h Nuclear Medicine Department , Centre Medico-Chirurgical Marie-Lannelongue , Le Plessis-Robinson , France.
Estelle
E
Blanc-Autran
i Hematology Department , Necker Hospital , Paris, France.
Richard
R
Delarue
j Service Onco-Hématologie Hôpital Saint Louis , Paris, France.
Christian
C
Gisselbrecht
k Clinique Bois-Cerf , Lausanne , Switzerland.
Nicolas
N
Ketterer
l Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse , France.
Christian
C
Recher
m Département de Médecine, Service d'Hématologie Clinique , CHU Liège, Campus Universitaire du Sart-Tilman , Belgique.
Christophe
C
Bonnet
n Department of Oncology , Antoine-Lacassagne Center , Nice , France.
Frederic
F
Peyrade
o Department of Hematology , Henri Mondor University Hospital , Créteil , France.
Corinne
C
Haioun
p Centre Henri-Becquerel , Université de Rouen , Rouen , France.
Hervé
H
Tilly
q Centre Hospitalier Lyon Sud , Service d'Hématologie, Hospices Civils de Lyon , Lyon , France.
Gilles
G
Salles
c Lymphoid Malignancies Unit , Saint Louis Hospital , Paris , France.
Pauline
P
Brice
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Didier
D
Bouscary
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Bénédicte
B
Deau
a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.|b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.
Jerome
J
Tamburini
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D005602:France; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
DLBCL; aa-IPI; primary bone lymphoma; radiotherapy; rituximab